

Table S1: Sample sizes of 21 tumor types before and after filtering to ensure sufficient mutations per sample.

| Cancer ^a | Sample size | Full (# mutations ≥ 6) | FoundationOne (# mutations ≥ 1) | PanCan (# mutations ≥ 1) | TrueSeq (# mutations ≥ 1) |
|---------------------|-------------|------------------------|---------------------------------|--------------------------|---------------------------|
| BLCA | 99 | 99 (100%) | 97(98%) | 95 (96%) | 84 (85%) |
| BRCA | 887 | 849 (96%) | 661 (75%) | 647 (73%) | 528 (60%) |
| CARC* | 54 | 53 (98%) | 26 (48%) | 13 (24%) | 10 (19%) |
| CLL* | 158 | 135 (85%) | 79 (50%) | 66 (42%) | 34 (22%) |
| CRC | 233 | 233 (100%) | 227 (97%) | 226 (97%) | 219 (94%) |
| DLBC* | 57 | 55 (96%) | 51 (89%) | 43 (75%) | 31 (54%) |
| ESO | 140 | 140 (100%) | 133 (95%) | 125 (89%) | 112 (80%) |
| GBM | 291 | 288 (99%) | 247 (85%) | 237 (81%) | 199 (68%) |
| HNSC | 384 | 372 (97%) | 357 (93%) | 347 (90%) | 303 (79%) |
| KIRC | 417 | 414 (99%) | 328 (79%) | 310 (74%) | 220 (53%) |
| LAML* | 194 | 126 (65%) | 132 (68%) | 131 (68%) | 77 (40%) |
| LUAD | 398 | 391 (98%) | 372 (93%) | 359 (90%) | 322 (81%) |
| LUSC | 176 | 176 (100%) | 176 (100%) | 175 (99%) | 158 (90%) |
| MED* | 89 | 42 (47%) | 26 (29%) | 24 (27%) | 15 (17%) |
| MEL | 118 | 118 (100%) | 117 (99%) | 113 (96%) | 112 (95%) |
| MM | 204 | 200 (98%) | 157 (77%) | 146 (72%) | 121(59%) |
| NB* | 75 | 18 (24.00%) | 49 (65%) | 61 (81%) | 62 (83%) |
| OV | 316 | 313 (99%) | 276 (87%) | 281 (89%) | 238 (75%) |
| PRAD* | 131 | 109 (83%) | 51 (39%) | 45 (34%) | 19 (15%) |
| RHAB* | 33 | 7 (21%) | 10 (30%) | 4 (12%) | 8 (24%) |
| UCEC | 247 | 247 (100%) | 245 (99%) | 242 (98%) | 229 (93%) |
| Total | 4701 | 4008 [†] | | | |

*Tumors excluded from NBS analysis due to insufficient mutations or samples

[†]Calculated after excluding tumor marked by *

^aBLCA-Bladder urothelial carcinoma; BRCA-Breast invasive carcinoma; CARC-Carcinoid; CLL-Chronic lymphocytic leukemia; CRC-Colorectal carcinoma; DLBC-Diffuse large B-cell lymphoma; ESO-Esophageal adenocarcinoma; GBM-Glioblastoma multiforme; HNSC-Head and neck squamous cell carcinoma; KIRC-Kidney renal clear cell carcinoma; LAML-Acute myeloid leukemia; LUAD-Lung adenocarcinoma; LUSC-Lung squamous cell carcinoma; MED-Medulloblastoma; MEL-Melanoma; MM-Multiple myeloma; OV-Ovarian serous cystadenocarcinoma; PRAD-Prostate adenocarcinoma; RHAB-Rhabdoid tumor; UCEC-Uterine corpus endometrial carcinoma

BLCA


K=3

K=4


K=5

K=6


Full



FoundationOne



PanCan



TrueSeq




Figure S1: The clustering patterns of BLCA across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank K=3,4,5,6.




Figure S2: The clustering patterns of BRCA across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank $K=3,4,5,6$.




Figure S3: The clustering patterns of CRC across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank K=3,4,5,6.


Full

K=3


K=4

K=5


K=6



FoundationOne



PanCan



TrueSeq




Figure S4: The clustering patterns of ESO across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank K=3,4,5,6.

GBM


K=3

K=4


K=5

K=6


Full



FoundationOne



PanCan



TrueSeq




Figure S5: The clustering patterns of GBM across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank K=3,4,5,6.

HNSC






Figure S6: The clustering patterns of HNSC across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank $K=3,4,5,6$.

KIRC


Full



FoundationOne



PanCan



TrueSeq





Figure S7: The clustering patterns of KIRC across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank $K=3,4,5,6$.

LUAD


K=3

K=4


K=5

K=6


Full



FoundationOne



PanCan



TrueSeq




Figure S8: The clustering patterns of LUAD across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank $K=3,4,5,6$.






Figure S9: The clustering patterns of LUSC across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank $K=3,4,5,6$.

K=3**K=4****K=5****K=6**


Full



FoundationOne



PanCan



TrueSeq





Figure S10: The clustering patterns of MEL across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank $K=3,4,5,6$.

MM




Figure S11: The clustering patterns of MM across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank $K=3,4,5,6$.

OV




Figure S12: The clustering patterns of OV across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank $K=3,4,5,6$.

UCEC


Full

K=3


K=4

K=5


K=6



FoundationOne



PanCan



TrueSeq




Figure S13: The clustering patterns of UCEC across the four gene sets (Full, FoundationOne, PanCan, and TrueSeq) and rank $K=3,4,5,6$.





Figure S14: NBS subtypes using the Full dataset and the associations with survival for three cancers, OV (A) and UCEC (B).




Figure S15: Subtypes associated with survival across different rank K 's for HNSC based on the TrueSeq panel. The sample subtype assignments for $K=4,5,6$, display an approximate nesting structure.




Figure S16: Subtypes associated with survival across different rank K 's for KIRC based on the PanCan panel. The sample subtype assignments for $K=3,4,5$, display an approximate nesting structure.




Figure S17: Subtypes associated with survival across different rank K 's for CRC based on the TrueSeq panel. The sample subtype assignments for $K=3,5$, display an approximate nesting structure.